Overview / Abstract: |
Rheumatoid arthritis (RA) is a chronic inflammatory joint disease that can cause bone and cartilage damage and lead to disability.1 RA affects about 24.5 million people, with 5 and 50 per 100,000 people newly developing the condition each year.1,2 RA has resulted in increased mortality in recent years, creating a need for an understanding of treat-to-target recommendations and appropriate disease activity measures.3 Adopting treat-to-target strategies in RA patients has shown great promise in improving RA outcomes.4 Treatments for RA continue to emerge along with advances in the understanding of its pathologic mechanisms and the development of drugs that target them.5 Many cytokines involved in controlling cell growth and the immune response in RA function by binding to and activating cytokine receptors, which in turn rely on the Janus kinase (JAK) family of enzymes for signal transduction. Disease-modifying antirheumatic drugs (DMARDs) inhibit the activity of these JAK enzymes and block cytokine signaling.6 Identifying the mechanistic profiles and clinical trial data for current and emerging targeted synthetic DMARDs can assist health care providers in optimizing RA patient outcomes.7 In this Clinical Issues™ program, an expert faculty panel will discuss and debate the latest insights into RA immunopathology with a focus on JAK enzyme activation, increase participants’ understanding of treat-to-target recommendations and appropriate disease activity measures, and describe the mechanistic profiles and clinical trial data for current and emerging targeted synthetic DMARDs. Attendees will leave this engaging program with new information and a fresh perspective on the evolving best practices for managing patients with RA. References: |
Expiration |
Oct 10, 2019 |
Discipline(s) |
Nurse Practitioner , Nursing CNE, Pharmacy CPE, Physician CME, Physician Assistant CME |
Format |
Seminar, Webinar / Webcast / Video |
Credits / Hours |
1.00 |
Accreditation |
ACCME, CME, CE |
Presenters / Authors / Faculty |
Rieke Alten, MD; Joel Kremer, MD, FACP; Josef Smolen, MD |
Sponsors / Supporters / Grant Providers |
This activity is jointly provided by Global Education Group and Integritas Communications. Based on a live symposium supported by an educational grant from Gilead Sciences, Inc. |
Keywords / Search Terms |
Integritas Communications RA, Rheumatoid Arthritis, CME, credit, CE, ACCME, DMARDs, integritas communications, EULAR Free CE CME |